Phospho-STAT2 (Y631) Antibody

Shipped with Ice Packs
In Stock

Description

Fundamental Characteristics of Phospho-STAT2 (Y631) Antibody

Phospho-STAT2 (Y631) Antibody is a polyclonal antibody developed to specifically recognize STAT2 protein only when phosphorylated at the tyrosine 631 residue. This site-specific recognition capability makes it invaluable for studying signal transduction mechanisms involving STAT2 activation. The antibody is derived from rabbit hosts and demonstrates high specificity with no cross-reactivity with other proteins or non-phosphorylated STAT2 .

These antibodies are typically produced by immunizing rabbits with synthetic peptides derived from human STAT2 protein sequences surrounding the phosphorylation site of tyrosine 631. The resulting antiserum undergoes affinity purification using epitope-specific immunogens to ensure high specificity and reduced background noise in experimental applications. The amino acid range covered by the immunogen typically spans residues 597-646 or 570-650, depending on the manufacturer .

The physical and biochemical properties of commercially available Phospho-STAT2 (Y631) antibodies include liquid formulations in phosphate-buffered saline (PBS) containing preservatives and stabilizers such as glycerol, bovine serum albumin (BSA), and sodium azide. The concentration is typically standardized at 1 mg/ml, making it convenient for laboratory use across various applications .

Applications and Experimental Utilities

Phospho-STAT2 (Y631) Antibody has been validated for multiple experimental applications, making it a versatile tool in molecular and cellular biology research. Each application requires specific optimization conditions to achieve reliable and reproducible results.

Validated Applications

The antibody has been rigorously tested and validated for several experimental techniques, with recommended dilution factors established for optimal performance.

ApplicationRecommended Dilution
Enzyme-Linked ImmunoSorbent Assay (ELISA)1:40000
Immunohistochemistry (IHC)1:100-1:300
Immunofluorescence (IF)Validated (dilution may vary by manufacturer)

These recommended dilutions serve as starting points for assay optimization. The actual working concentration may vary depending on specific experimental conditions, sample types, and detection methods employed. Researchers are advised to perform titration experiments to determine the optimal antibody concentration for their specific applications .

Experimental Considerations

When working with Phospho-STAT2 (Y631) Antibody, several experimental considerations should be taken into account to ensure reliable results. The phosphorylation state of proteins can be labile and sensitive to sample preparation methods. Therefore, proper sample handling, including the use of phosphatase inhibitors during protein extraction, is essential to preserve the phosphorylation status of STAT2 at tyrosine 631.

For immunohistochemistry applications, appropriate antigen retrieval methods may be necessary to expose the phospho-epitope. The choice between heat-induced epitope retrieval (HIER) and enzymatic antigen retrieval should be empirically determined for each tissue type and fixation method. Additionally, blocking endogenous peroxidase activity and preventing non-specific binding are critical steps to minimize background staining and increase the signal-to-noise ratio .

In ELISA applications, the extraordinarily high dilution factor (1:40000) suggested for some commercial variants of this antibody indicates its high sensitivity and affinity for the phosphorylated epitope. This high sensitivity makes it particularly valuable for quantitative detection of phosphorylated STAT2 in complex biological samples .

Biological Significance of STAT2 and Y631 Phosphorylation

Understanding the biological significance of STAT2 and specifically the Y631 phosphorylation site provides important context for the utility of Phospho-STAT2 (Y631) Antibody in research applications. This knowledge helps researchers interpret experimental results and design appropriate studies.

STAT2 Structure and Function

STAT2 is a critical component of the interferon signaling pathway, functioning as a signal transducer and transcription factor. As a member of the STAT protein family, STAT2 plays a pivotal role in mediating cellular responses to cytokines and growth factors. The protein has a molecular weight of approximately 113 kDa and contains several functional domains including an SH2 domain, a DNA-binding domain, and transactivation domains .

In response to interferons (IFNs), particularly type I interferons like IFN-α and IFN-β, STAT2 becomes activated through phosphorylation. This activation prompts STAT2 to form a heterotrimeric complex with STAT1 and interferon regulatory factor 9 (IRF9, also known as p48 or ISGF3G). This complex, known as Interferon-Stimulated Gene Factor 3 (ISGF3), translocates to the nucleus where it binds to specific DNA sequences called Interferon-Stimulated Response Elements (ISREs) to initiate transcription of interferon-stimulated genes (ISGs) .

Unlike other STAT family members, STAT2 lacks direct DNA-binding capability. Instead, within the ISGF3 complex, STAT2 functions primarily as a transactivator, while STAT1 and IRF9 provide the DNA-binding functionality. This unique characteristic distinguishes STAT2 from other members of the STAT family and highlights its specialized role in interferon signaling .

Significance of Y631 Phosphorylation

The phosphorylation of STAT2 at tyrosine 631 (Y631) represents a critical regulatory mechanism in the interferon signaling pathway. This specific phosphorylation event is typically catalyzed by Janus kinases (JAKs) that are associated with interferon receptors. Upon interferon binding to its receptor, receptor-associated JAKs become activated and phosphorylate STAT2 at Y631, which is essential for subsequent STAT2 activation and function.

Y631 phosphorylation facilitates the interaction between STAT2 and STAT1, promoting heterodimer formation and subsequent assembly of the ISGF3 complex. This phosphorylation-dependent complex formation is a prerequisite for nuclear translocation and transcriptional regulation of interferon-responsive genes. Consequently, monitoring the phosphorylation status of STAT2 at Y631 using Phospho-STAT2 (Y631) Antibody provides valuable insights into the activation state of the interferon signaling pathway .

Research Applications and Significance

Phospho-STAT2 (Y631) Antibody has significant applications in various research fields, particularly in studies involving immune responses, viral infections, and inflammatory conditions. Its ability to specifically detect activated STAT2 makes it an invaluable tool for understanding signaling mechanisms and disease processes.

Immunological and Virological Research

In immunological research, this antibody allows scientists to monitor interferon signaling pathways that are critical for host defense against pathogens. By detecting phosphorylated STAT2, researchers can assess the activation status of the interferon response in various experimental conditions, including viral infections, autoimmune diseases, and inflammatory disorders.

The interferon pathway, in which STAT2 plays a crucial role, represents the first line of defense against viral infections. Many viruses have evolved mechanisms to inhibit this pathway, often targeting STAT2 function or its phosphorylation. Phospho-STAT2 (Y631) Antibody enables researchers to investigate these viral evasion strategies and understand how they impact interferon signaling and antiviral immunity .

Additionally, this antibody can be utilized to evaluate the efficacy of therapeutic agents designed to modulate the interferon response. Compounds that enhance or inhibit STAT2 phosphorylation can be screened and characterized using this antibody, facilitating drug discovery efforts aimed at treating viral infections, inflammatory diseases, and certain cancers where interferon signaling is implicated.

Molecular and Cellular Biology Applications

In molecular and cellular biology, Phospho-STAT2 (Y631) Antibody serves as a valuable tool for investigating signal transduction mechanisms. The antibody can be employed to track the spatiotemporal dynamics of STAT2 activation following stimulation with interferons or other cytokines, providing insights into the kinetics and regulation of this signaling pathway.

Furthermore, this antibody facilitates the study of protein-protein interactions involving phosphorylated STAT2. Co-immunoprecipitation experiments using Phospho-STAT2 (Y631) Antibody can identify novel interaction partners that specifically recognize the phosphorylated form of STAT2, expanding our understanding of the molecular mechanisms underlying interferon signaling.

The antibody also supports research on post-translational modifications beyond phosphorylation. The crosstalk between different modifications (such as phosphorylation, ubiquitination, SUMOylation, and acetylation) in regulating STAT2 function can be investigated using this antibody in combination with other modification-specific antibodies .

Quality Control and Validation

Quality control and validation procedures are essential aspects of antibody production and characterization, ensuring the reliability and reproducibility of experimental results obtained with Phospho-STAT2 (Y631) Antibody.

Validation Methodologies

Commercial suppliers of Phospho-STAT2 (Y631) Antibody implement rigorous validation protocols to confirm the specificity and sensitivity of their products. These validation procedures typically include multiple experimental approaches to verify that the antibody specifically recognizes phosphorylated STAT2 at tyrosine 631 without cross-reactivity to non-phosphorylated STAT2 or other phosphorylated proteins.

Validation methods commonly include Western blotting/immunoblotting with positive control samples (cells treated with interferon to induce STAT2 phosphorylation) and negative control samples (untreated cells or cells treated with phosphatase inhibitors). Additional validation approaches may involve immunohistochemistry, immunofluorescence, and ELISA using known positive and negative samples. Some manufacturers also perform phosphopeptide competition assays, where the antibody is pre-incubated with phosphorylated and non-phosphorylated peptides to confirm specificity for the phosphorylated form .

The absence of cross-reactivity with other proteins is an important quality attribute of Phospho-STAT2 (Y631) Antibody. Manufacturers verify this by testing the antibody against a panel of cell lysates or tissue samples expressing various proteins that might potentially cross-react with the antibody. The documented lack of cross-reactivity enhances the reliability of experimental results obtained with this antibody .

Performance Characteristics

The performance characteristics of Phospho-STAT2 (Y631) Antibody, including sensitivity, specificity, and reproducibility, determine its utility in various research applications. High sensitivity enables the detection of low levels of phosphorylated STAT2, which is particularly important when studying early events in signaling cascades or samples with limited amounts of target protein.

Specificity for the phosphorylated form of STAT2 is achieved through careful design of the immunogen and thorough purification procedures. The antibody specifically recognizes STAT2 when phosphorylated at tyrosine 631, without binding to non-phosphorylated STAT2 or other phosphorylated proteins. This high specificity minimizes false positive results and ensures accurate interpretation of experimental data .

Batch-to-batch reproducibility is maintained through standardized production processes and quality control measures. Each lot of antibody undergoes testing to verify consistent performance across multiple applications, ensuring that researchers can obtain reliable and reproducible results regardless of which batch they use .

Product Specs

Buffer
The antibody is provided as a liquid solution in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide.
Form
Liquid
Lead Time
Typically, we can ship your order within 1-3 business days of receiving it. Delivery time may vary depending on your location and shipping method. Please consult your local distributor for specific delivery timeframes.
Synonyms
Homo sapiens interferon alpha induced transcriptional activator antibody; interferon alpha induced transcriptional activator antibody; ISGF 3 antibody; ISGF3 antibody; MGC59816 antibody; P113 antibody; signal transducer and activator of transcription 2 113kD antibody; Signal transducer and activator of transcription 2 antibody; STAT113 antibody; Stat2 antibody; STAT2_HUMAN antibody
Target Names
Uniprot No.

Target Background

Function
STAT2 is a signal transducer and activator of transcription protein that mediates signaling by type I interferons (IFN-alpha and IFN-beta). When type I IFNs bind to cell surface receptors, Jak kinases (TYK2 and JAK1) are activated, leading to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerize and associate with IRF9/ISGF3G, forming a complex called the ISGF3 transcription factor. This complex then enters the nucleus and binds to the IFN-stimulated response element (ISRE) to activate the transcription of interferon-stimulated genes. This process ultimately drives the cell into an antiviral state. Additionally, STAT2 plays a negative feedback regulatory role in type I interferon signaling by recruiting USP18 to the type I IFN receptor subunit IFNAR2, thereby mitigating the response to type I IFNs. STAT2 also acts as a regulator of mitochondrial fission by modulating the phosphorylation of DNM1L at Ser-616 and Ser-637, which activate and inactivate the GTPase activity of DNM1L respectively.
Gene References Into Functions
  1. Priming cells with IFNbeta synergistically enhances IL6 induction in response to treatments that activate NF-kappaB, in a process that depends upon the recruitment of STAT2 and IRF9. PMID: 29581268
  2. Surface features in the interacting domains of IRF9 and STAT2 have diverged to enable specific interaction between these family members and facilitate the antiviral response. PMID: 29317535
  3. mRNA expression of survivin was positively correlated with STAT2 mRNA in psoriasis vulgaris lesion tissues. PMID: 29089085
  4. Based on the proposition that NS5 utilizes SIAH2-mediated proteasomal degradation of STAT2, an in-silico study was carried out to characterize the protein-protein interactions between NS5, SIAH2 and STAT2 proteins. PMID: 28365387
  5. The pathways related to tumorigenicity and tumor progression, STAT2 and AdipoR1/AMPK/SIRT1, could be restrained by miR-3908. In conclusion, restoration of miR-3908 expression induced suppression of cancer progression and glioblastoma tumorigenicity. PMID: 28440504
  6. This study highlights the existence of a STAT1-independent IFN-I signaling pathway, where STAT2/IRF9 can potentially substitute for the role of ISGF3 and offer a back-up response against viral infection. PMID: 27053489
  7. Decreased phosphorylated STAT2 expression was accompanied by increased replication of hepatitis C virus and hepatitis E virus. PMID: 28442624
  8. Data suggest that STAT2 plays a role in the psoriasis pathogenesis by regulating the expression of CXCL11 and CCL5, and thereby attracting IFNgamma-producing immune cells to the skin. PMID: 28472186
  9. Interferon-alpha-enhanced IL-10 expression in human CD4 T cells is regulated by STAT3, STAT2, and BATF transcription factors. PMID: 28242623
  10. The rate-limiting transition state for binding between the TAZ1 domain of CREB binding protein and the intrinsically disordered transactivation domain of STAT2 (TAD-STAT2) was determined by site-directed mutagenesis and kinetic experiments (Phi-value analysis). It was found that the native protein-protein binding interface is not formed at the transition state for binding. PMID: 28707474
  11. These studies identify phosphorylation of S734-STAT2 as a new regulatory mechanism that negatively controls the type I IFN-antiviral response. PMID: 27802159
  12. This study demonstrates that overexpression of Porcine deltacoronavirus (PDCoV) nsp5 also antagonizes IFN signaling by cleaving STAT2, an essential component of transcription factor complex ISGF3, and that PDCoV infection reduces the levels of STAT2, which may affect the innate immune response. PMID: 28250121
  13. PKV VP3 associated with STAT2 and IRF9, and interfered with the formation of the STAT2-IRF9 and STAT2-STAT2 complex. PMID: 28441586
  14. The authors have discovered a novel phosphorylation of STAT2 on T387 that negatively regulates signal from the type I interferon receptor to the genome by transcription factor ISGF3. PMID: 27852626
  15. STAT2 recruits USP18 to the type I IFN receptor subunit IFNAR2 via its constitutive membrane-distal STAT2-binding site. PMID: 28165510
  16. These findings indicate that overexpression of IFITM1 enhances the aggressive phenotype of triple-negative SUM149 IBC cells and that this effect is dependent on STAT2/BRG1 interaction. PMID: 26897526
  17. IFN-beta exhibited significant cytotoxicity in HepG2 cells mainly through phosphorylation of STAT2. PMID: 25773664
  18. STAT2 rs2066807 polymorphism is not associated with cervical cancer. PMID: 25921106
  19. Respiratory syncytial virus NS1 upregulates SOCS1 expression in a RIG-I- and TLR3-independent pathway, to inhibit STAT2 phosphorylation. PMID: 24480984
  20. Data indicate that the RVB1/2 chromatin-remodeling complex is required for efficient Pol II recruitment and initiation at IFN-alpha-stimulated genes (ISGs) promoters and is recruited through interaction with the STAT2 transactivation domain. PMID: 23878400
  21. Dengue virus co-opts UBR4 to degrade STAT2 and antagonize type I interferon signaling. PMID: 23555265
  22. Sequencing of genomic DNA and RNA revealed a homozygous mutation in intron 4 of STAT2 that prevented correct splicing in patient cells. PMID: 23391734
  23. In systemic lupus erythematosus but not in healthy control leukocytes, Jak1 and STAT2 were constitutively phosphorylated, even in the absence of disease activity. PMID: 22859983
  24. STAT2 serine 287 is a novel regulatory phosphorylation site in type I interferon-induced cellular responses. PMID: 23139419
  25. These results indicate the importance that herpes simplex virus 2 has assigned to STAT2, investing significant genomic currency throughout its replicative lifecycle for continuous targeted destruction and inhibition of this protein. PMID: 22634037
  26. A haplotype at STAT2 introgressed from neanderthals serves as a candidate of positive selection in Papua New Guinea. PMID: 22883142
  27. STAT2 is functionally involved in the immunosuppressive activity of hcMSCs as a novel regulator under inflammatory conditions. PMID: 22523757
  28. Co-immunoprecipitation/immunoblot analyses showed that STAT2 enhanced RCAN1 ubiquitination through the ubiquitin E3 ligase FBW7.. PMID: 22426484
  29. Data show that, in response to IFNalpha, STAT2 is recruited onto the endogenous P2p73 promoter together with the polycomb group protein Ezh2. PMID: 21399658
  30. Chromatin dynamics of gene activation and repression in response to interferon alpha (IFN(alpha)) reveal new roles for phosphorylated and unphosphorylated forms of the transcription factor STAT2. PMID: 21498520
  31. STAT2 may interact with IRF-9 in a STAT1-independent manner. The complex STAT2/IRF-9 is the key factor mediating the expression of RIG-G gene regulated by IFN-alpha. PMID: 20403236
  32. Signals ensued by IFN-alpha and IL-4 induce cytoplasmic sequestration of IL-4-activated STAT6 and IFN-alpha-activated STAT2:p48 in B cells through the formation of pY-STAT6:pY-STAT2:p48 complex. PMID: 21268015
  33. Dengue virus 2 NS5 is able to bind and degrade human STAT2. PMID: 21075352
  34. STAT2 and IRF-1 compete at binding interferon-stimulated response elements (ISREs) located on the retinoic acid-induced gene G (RIG-G) promoter in RIG-G. PMID: 20533260
  35. Defects in the expression or nuclear localization of STAT2 could lessen the efficacy of type I IFN immunotherapy. PMID: 20068068
  36. In this study, we characterized the Stat2-IFNaR2 interaction and examined its role in IFNalpha signaling. PMID: 11786546
  37. IFNtau did not affect IRF-1 expression in Stat2-deficient cells. PMID: 11804954
  38. STAT2 acts as a host range determinant for species-specific paramyxovirus interferon antagonism and simian virus 5 replication. PMID: 12050355
  39. Stat2 binds more avidly to subunit 2 of the interferon alpha receptor (IRNaR2) than to phosphorylated IFNaR1. PMID: 12220192
  40. Nipah virus V protein evades alpha and gamma interferons by preventing STAT2 activation and nuclear accumulation. PMID: 12388709
  41. Results suggest that the STAT2 activation process is a crucial target for the blockade of IFN-alpha signaling. PMID: 12610111
  42. Measles virus V protein blocks INF-alpha/beta by inhibiting STAT2 phosphorylation. PMID: 12804771
  43. Hendra virus V protein inhibits cellular responses to IFN through binding and cytoplasmic sequestration of STAT2. PMID: 14557668
  44. There is a critical motif in Stat2 required for its transcriptional activity, and resistance to type one IFNs can be mediated by mutations in Stat2. PMID: 14722125
  45. Expression of STAT-2 is induced by Epstein-Barr virus (EBV) LMP-1 (latent membrane protein) and may be part of the viral programming that regulates viral latency and cellular transformation. PMID: 15165826
  46. The regulation of STAT2 nuclear trafficking is distinct from the previously characterized STAT1 factor. PMID: 15175343
  47. IFNalpha-induced nuclear accumulation of STAT2 was partially blocked in cell lines expressing high levels of HCV core protein. Subsequently, PMID: 15221897
  48. STAT2 activation and interferon signaling are blocked by West Nile Virus nonstructural proteins. PMID: 15650219
  49. The conserved DNA-binding domain of STAT2 has a role specific to the activity of ISGF3-independent STAT2-containing complexes. PMID: 15668228
  50. IFNaR2 intracellular domain transcriptional modulation is dependent upon the carboxyl-terminal transactivation domain of Stat2. PMID: 15717316

Show More

Hide All

Database Links

HGNC: 11363

OMIM: 600556

KEGG: hsa:6773

STRING: 9606.ENSP00000315768

UniGene: Hs.530595

Involvement In Disease
Immunodeficiency 44 (IMD44)
Protein Families
Transcription factor STAT family
Subcellular Location
Cytoplasm. Nucleus.

Q&A

What is STAT2 and why is the Y631 residue significant?

STAT2 is a 113kDa member of the Signal Transducer and Activator of Transcription family that plays a critical role in type I interferon (IFN) signaling. Following IFN receptor activation, STAT2 is phosphorylated, dimerizes with STAT1, and partners with IRF9 to form the ISGF3 complex that drives transcription of interferon-stimulated genes .

The Y631 residue is part of a conserved motif (PYTK) consisting of proline 630, tyrosine 631, threonine 632, and lysine 633 that regulates STAT protein function . Interestingly, while Y631 itself is not phosphorylated, it plays a critical regulatory role in STAT signaling. Mutation studies have shown that converting Y631 to phenylalanine (Y631F) prolongs STAT1 activation and ISGF3 signaling by decreasing STAT1 dephosphorylation, making this a key regulatory site for interferon response duration .

What applications can Phospho-STAT2 (Y631) antibodies be used for?

Phospho-STAT2 (Y631) antibodies can be utilized in multiple experimental applications:

ApplicationTypical DilutionNotes
Immunohistochemistry (IHC)1:100-1:300Works with paraffin-embedded tissues
Immunofluorescence (IF)1:50-1:200For subcellular localization studies
Western Blot (WB)1:1000-1:2000For protein detection in cell lysates
ELISA1:40000For quantitative analysis

These antibodies are specifically designed to detect endogenous levels of STAT2 protein only when phosphorylated at Y631, providing researchers with a tool to study this regulatory modification .

How does Phospho-STAT2 (Y631) differ from Phospho-STAT2 (Y690)?

These two phosphorylation sites serve distinct functions in STAT2 signaling:

  • Y690: The primary tyrosine phosphorylation site in STAT2, phosphorylated by JAK1/TYK2 kinases following interferon receptor activation. This phosphorylation is essential for STAT2 activation, dimerization with STAT1, and formation of the ISGF3 complex .

  • Y631: Not directly phosphorylated but plays a regulatory role. The Y631F mutation prolongs STAT1 activation by decreasing dephosphorylation rates . It functions as part of the PYTK motif that modulates the duration and intensity of interferon signaling.

When designing experiments, researchers should carefully select antibodies specific to the phosphorylation site relevant to their research question.

What species reactivity does Phospho-STAT2 (Y631) antibody exhibit?

Commercially available Phospho-STAT2 (Y631) antibodies typically demonstrate reactivity with:

  • Human: Confirmed reactivity in multiple cell lines and tissues

  • Mouse: Validated for mouse samples

  • Rat: Validated for rat samples

Some antibodies may have predicted cross-reactivity with additional species such as pig, bovine, horse, and Xenopus . When planning experiments with non-standard model organisms, researchers should verify reactivity through pilot studies.

How do mutations in the PYTK motif affect STAT2 function?

The PYTK motif (P630-Y631-T632-K633) contains two critical regulatory residues with opposing effects on STAT2 signaling:

P630 (Proline 630):

  • Mutation to leucine (P630L) reduces ISGF3 signaling by impairing STAT2 tyrosine phosphorylation

  • P630L mutation abrogates IFN-α induced apoptosis

  • This mutation was found to emerge under IFN-α selection pressure

Y631 (Tyrosine 631):

  • Y631F mutation prolongs STAT1 activation and ISGF3 signaling

  • This effect occurs through decreased STAT1 dephosphorylation

  • Y631F promotes the apoptotic effects of IFN-α, opposite to P630L

The proximity and opposing effects of these mutations suggest that the P630-Y631 region forms a critical structural motif influencing both activation and deactivation phases of STAT2 signaling. The proline at position 630 likely creates a specific conformation important for proper STAT2 phosphorylation, while Y631 appears to be involved in regulating signal termination .

What is the interplay between different phosphorylation sites in STAT2?

STAT2 contains multiple phosphorylation sites that work in concert to regulate interferon signaling:

Phosphorylation SiteFunctionEffect of Mutation
Y690Primary activation site phosphorylated by JAK1/TYK2Y690F mutation prevents STAT2 activation and ISGF3 formation
Y631Regulatory role (not directly phosphorylated)Y631F mutation prolongs STAT1 activation by decreasing dephosphorylation
S287Negative regulatory site in coiled-coil domainS287A enhances IFN-α effects; S287D impairs STAT2 activity

The S287 site is particularly interesting as a novel regulatory serine residue. When S287 is mutated to alanine (preventing phosphorylation), it generates a gain-of-function STAT2 that enhances IFN-α effects, including:

  • Increased cell growth inhibition

  • Prolonged protection against vesicular stomatitis virus infection

  • Enhanced transcriptional responses

  • Prolonged Y690 phosphorylation

Conversely, the phosphomimetic S287D mutation dramatically impairs STAT2 transcriptional activity and reduces nuclear translocation .

How can researchers validate the specificity of Phospho-STAT2 (Y631) antibodies?

Rigorous validation is critical for phospho-specific antibodies. Researchers should implement the following methodological approaches:

  • Positive and Negative Controls:

    • Positive: Cells treated with type I interferons (500-1000 U/mL IFN-α/β for 20-30 minutes)

    • Negative: Untreated cells or cells pre-treated with JAK inhibitors

  • Peptide Competition Assay:

    • Pre-incubate antibody with immunizing phosphopeptide

    • Signal should be blocked by specific phosphopeptide but not by non-phosphorylated peptide

  • Genetic Approaches:

    • Compare signal in STAT2-knockout cells (e.g., U6A cell line) reconstituted with wild-type vs. mutant STAT2

    • Y631F mutant expression should alter signaling dynamics compared to wild-type

  • Phosphatase Treatment:

    • Treat one sample of lysate with lambda phosphatase

    • Compare signal between treated and untreated samples

  • Signal Specificity Controls:

    • Test for cross-reactivity with other phosphorylated STAT proteins

    • Verify antibody doesn't recognize other phospho-tyrosine proteins

Proper validation ensures reliable results and prevents misinterpretation of experimental data.

What are optimal experimental conditions for detecting STAT2 activation in different cell types?

Optimizing experimental conditions is essential for robust detection of STAT2 phosphorylation:

Stimulation Parameters:

  • Type I interferons: 500-1000 U/mL for most cell types

  • Optimal stimulation time: 20-30 minutes for peak phosphorylation

  • Serum starvation (overnight) enhances signal-to-noise ratio

Cell Type-Specific Considerations:

Cell TypeRecommended ConditionsSpecial Considerations
Immune cells (e.g., Daudi)250-500 U/mL IFN, 15-20 minRespond robustly to lower IFN doses
Epithelial cells (e.g., HeLa)1000 U/mL IFN, 30-45 minMay require higher IFN concentrations
Fibroblasts500-1000 U/mL, 30-60 minOften show more sustained phosphorylation
Primary cells100-500 U/mL, 15-30 minMore sensitive than cell lines; rapid processing critical

Western Blot Optimization:

  • Load 30-50μg total protein per lane

  • Use PVDF membrane (preferred over nitrocellulose for phospho-proteins)

  • Block in 5% BSA (not milk, which contains phospho-proteins)

  • Primary antibody dilution: 1:1000 to 1:2000, incubate overnight at 4°C

Immunofluorescence/IHC Considerations:

  • Fixation: 4% paraformaldehyde (10 min) followed by methanol permeabilization

  • Antibody dilution: 1:50 to 1:200 range

  • Include antigen retrieval for paraffin sections (Tris-EDTA, pH 9.0)

How can phospho-STAT2 analysis be integrated into multi-parameter studies of interferon signaling?

For comprehensive analysis of interferon signaling networks:

  • Multiplexed Western Blotting:

    • Sequential immunoblotting with stripping between antibodies

    • Analyze multiple parameters on the same membrane:

      • Phospho-STAT2 (Y631)

      • Phospho-STAT2 (Y690)

      • Total STAT2

      • Phospho-STAT1 (Y701)

      • Phospho-JAK1/TYK2

  • Multi-Color Flow Cytometry:

    • Simultaneously detect multiple phospho-proteins at single-cell level

    • Example panel design:

      • Phospho-STAT2 (Y631) - Alexa Fluor 488

      • Phospho-STAT2 (Y690) - PE

      • Phospho-STAT1 (Y701) - Alexa Fluor 647

      • Total STAT2 - PE-Cy7

  • Kinetic Analysis:

    • Perform time-course experiments (5, 15, 30, 60, 120 min post-stimulation)

    • Measure multiple phosphorylation events at each timepoint

    • Compare wild-type vs. Y631F STAT2 to reveal regulatory mechanisms

    • Include phosphatase inhibitors at different timepoints to assess dephosphorylation kinetics

  • Genetic Approaches:

    • Compare cells expressing STAT2 mutations:

      • Y631F mutation

      • P630L mutation

      • Y690F mutation

      • S287A/D mutations

    • Analyze effects on multiple pathway components simultaneously

What controls should be included when using Phospho-STAT2 (Y631) antibodies?

Proper experimental controls are essential for interpreting results with phospho-specific antibodies:

Positive Controls:

  • Cell lysates from interferon-stimulated cells (e.g., Daudi cells treated with 500 U/mL IFN-α for 20 minutes)

  • Positive control lysates provided by antibody manufacturers

Negative Controls:

  • Unstimulated cell lysates

  • Lysates from cells pre-treated with JAK inhibitors (e.g., Ruxolitinib, Tofacitinib)

  • Phosphatase-treated positive control lysates

Specificity Controls:

  • Peptide competition with phospho-peptide vs. non-phospho-peptide

  • Isotype control antibodies at equivalent concentration

Genetic Controls:

  • STAT2-deficient cells (e.g., U6A cell line)

  • Cells expressing Y631F or other STAT2 mutants

The inclusion of these controls helps validate antibody specificity and ensures accurate interpretation of experimental results.

How should researchers optimize detection methods for low abundance phospho-STAT2?

When working with samples where phospho-STAT2 is present at low abundance:

  • Sample Enrichment Techniques:

    • Immunoprecipitation with total STAT2 antibody followed by phospho-STAT2 detection

    • Phospho-tyrosine enrichment using anti-pTyr antibodies

    • Subcellular fractionation to concentrate nuclear fractions where activated STAT2 resides

  • Signal Amplification Methods:

    • Enhanced chemiluminescence (ECL) substrates with extended sensitivity

    • Tyramide signal amplification for immunohistochemistry

    • Biotin-streptavidin amplification systems

  • Optimization of Blocking and Antibody Conditions:

    • Extend primary antibody incubation time (overnight at 4°C)

    • Test different blocking agents (BSA, commercial blockers, normal serum)

    • Optimize antibody dilution through titration experiments

  • Technical Considerations:

    • Use fresh phosphatase inhibitors in all buffers

    • Process samples rapidly to prevent dephosphorylation

    • Consider using PVDF membranes with smaller pore size (0.2μm) for Western blotting

    • Increase exposure time incrementally while monitoring background

These methodological refinements can significantly improve detection sensitivity while maintaining specificity.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.